Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat
Tóm tắt
Diabetes mellitus is characterized by having a multitude of life-threatening secondary complications, particularly dyslipidemia, which ultimately leads to the development of comorbid diseases, such as cardiovascular diseases. This research work was designed to investigate the synergistic effect of glimepiride (1 mg/kg b.w.) and rosuvastatin (10 mg /kg b.w.) on alloxan-induced diabetic rats having dyslipidemia. Diabetes was induced by injecting alloxan (120 mg/kg b.w.) intraperitoneally. The experiment was conducted to determine the level of blood glucose, HbA1c, lipid profile, and body weight variation of rats. This study’s outcomes suggested that the combination therapy showed more statistically significant effect on blood glucose level, HbA1c level, lipid profile, and body weight variation than any single therapy. While the glimepiride monotherapy showed a statistically considerable effect on blood glucose level, HbA1c level, and body weight variation, the rosuvastatin treated group gave statistically non-significant effect on these parameters except body weight variation, which was found as downward trend. In addition, the rosuvastatin treated group showed a healthy lipid profile compared to glimepiride treated group. Concluding the results of this study, it can be said that the treatment of glimepiride in combination with rosuvastatin may be more efficacious than monotherapy for preventing diabetes in rats with dyslipidemia.
Tài liệu tham khảo
Kennedy MSN, Masharani U. Pancreatic Hormones & Antidiabetic Drugs. In: Katzung BG, editor. Basic Clin Pharmacol a LANGE Med B. 14th ed. McGraw-Hill Education; 2018. p. 747–771.
Philipson LH, Steiner DF. Pas de deux or more: The sulfonylurea receptor and K+ channels. Science. 1995;268:372–3.
Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: A review of the worldwide therapeutic experience. Clin Ther. 2003;25:799–816.
Jeng C-Y, Hollenbeck CB, Wu MS, Foley JE, Chen Y-DI, Reaven GM. Changes in carbohydrate metabolism in association with glipizide treatment of type 2 diabetes. Diabet Med. 1991;8:32–9.
Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olefsky JM. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984;33:346–54.
Feldman JM, Lebovitz HE, Lebovitz L. Endocrine and metabolic effects of Glybenclamide: evidence for an Extrapancreatic mechanism of action. Diabetes. 1971;20:745–55.
Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2010;6:225–35.
Matafome P, Louro T, Rodrigues L, Crisóstomo J, Nunes E, Amaral C, et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev. 2011;27:54–62.
Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001;38:1307–10.
Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2010;6:225–35.
Caro JJ, Ward AJ, O’Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care. 2002;25:476–81.
Toh SA, Rader DJ. Dyslipidemia in insulin resistance: Clinical challenges and adipocentric therapeutic frontiers. Expert Rev Cardiovasc Ther. 2008;6:1007–22.
Taskinen MR. Diabetic dyslipidaemia: From basic research to clinical practice. Diabetologia. 2003;46:733–49.
Nii D, Tagoe A, Amo-Kodieh P. Type 2 diabetes mellitus influences lipid profile of diabetic patients. Sch Res Libr Ann Biol Res. 2013;4:88–92.
Syvänne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 1997;350:20–3.
Ikeoka D, Krusinova E. Insulin resistance and lipid metabolism. Rev Assoc Med Bras. 2009;55:234.
Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: Extending treatment beyond statins in the high-risk cardiovascular patient. Heart. 2011;97:350–6.
Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150–9.
Mahboob A, Taqweem A, Alam I, Ahmad I, Ali Z, Bilal M. Effect of pioglitazone on lipid profile in type 2 diabetic patients. J Postgrad Med Inst. 2013;27:13–9.
Lamb RE, Goldstein BJ. Modulating an oxidative-inflammatory cascade: Potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int J Clin Pract. 2008;62:1087–95.
Pieroni A, Nebel S, Quave C, Münz H, Heinrich M. Ethnopharmacology of liakra: traditional weedy vegetables of the Arbëreshë of the vulture area in southern Italy. J Ethnopharmacol. 2002;81:165–85.
McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl. 2003;4:9–14.
Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005;95:360–6.
Ooi EMM, Nestelmd PJ, Watts GF, Sviridov D, Chan DC, Barrett PHR, et al. Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome. Diabetes Care. 2008;31:1656–61.
Bayrasheva VK, Babenko AY, Dobronravov VA, Dmitriev Y V., Chefu SG, Pchelin IY, et al. Uninephrectomized High-Fat-Fed Nicotinamide-Streptozotocin-Induced Diabetic Rats: A Model for the Investigation of Diabetic Nephropathy in Type 2 Diabetes. J Diab Res. 2016;2016:1–18.
Iams SG, Wexler BC. Alloxan diabetes in spontaneously hypertensive rats: gravimetric, metabolic and histopathological alterations. Br J Exp Pathol. 1977;58:177–99.
Xiong G, P. Murali D. Combination drug therapy for Alzheimer’s disease. Geriatrics. 2005;60:22–6.
Orloff DG. Fixed combination drugs for cardiovascular disease risk reduction: Regulatory approach. Am J Cardiol. 2005;96:28–33.
Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetol Metab Syndr. 2010;2:44.
Sever PS, Messerli FH. Hypertension management 2011: Optimal combination therapy. Eur Heart J. Oxford Academic; 2011;32:2499–506.
Miersch S, Sliskovic I, Raturi A, Mutus B. Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes. Free Radic Biol Med. 2007;42:270–9.
Piconi L, Corgnali M, Da Ros R, Assaloni R, Piliego T, Ceriello A. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose. J Diabetes Complicat. 2008;22:38–45.
Kaneto H, Kajimoto Y, Miyagawa J, Matsuoka T, Fujitani Y, Umayahara Y, et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic β-cells against glucose toxicity. Diabetes. American Diabetes Association Inc. 1999;48:2398–406.
Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, et al. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10mg+ metformin SR 500mg in diabetic dyslipidaemia in adult Indian patients. J Indian Med Assoc. 2008;106:464–7.
Abedulla Khan K, Satyanarayana S, Eswar Kumar K, Anupama K. Pharmacodynamic drug interaction of mexiletine with metformin in rats. Res J Pharm Biol Chem Sci. 2012;3:905–11.
Draeger KE, Wernicke-Panten K, Lomp HJ, Schüler E, Roßkamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent climepiride (Amaryl®): A double-blind comparison with clibenclamide. Horm Metab Res. Georg Thieme Verlag; 1996;28:419–25.
Sonnenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, et al. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother. New York: SAGE Publications Inc.; 1997;31:671–676.
Draeger E. Clinical profile of glimepiride. Diabetes Res Clin Pract. 1995;28:S139–46.
Weitgasser R, Lechleitner M, Luger A, Klingler A. Effects of glimepiride on HbA1c and body weight in type 2 diabetes: results of a 1.5-year follow-up study. Diabetes Res Clin Pract. 2003;61:13–9.
Tsutamoto T, Yamaji M, Kawahara C, Nishiyama K, Fujii M, Yamamoto T, et al. Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. Eur J Heart Fail. 2009;11:1195–201.
Jenkins DJA, Thompson AL, Wolever TMS, Vuksan V, Rao A V., Thompson LU, et al. Effect of reduced rate of carbohydrate absorption on carbohydrate and lipid metabolism. Eur J Clin Nutr. 1995;49:S68-73.
Islam MS, Alam AHMK, Rahman MAA, Ali Y, Mamun A, Rahman M, et al. Effects of combination of Antidiabetic agent and statin on Alloxan-induced diabetes with cardiovascular diseases in rats. J Sci Res. 2012;4:709–20.
Md TI SN. Beneficiary Effect of Combination Therapy of Metformin and Pitavastatin Drug on Alloxan Induced Diabetic Rats Comparing to Single Drug Therapy. Clin Exp Pharmacol. 2016;06:2161–1459.
Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs. 2000;60:95–113.
Babu V, Gangadevi T, Subramoniam A. Anti-hyperglycaemic activity of Cassia kleinii leaf extract in glucose fed normal rats and alloxan-induced diabetic rats. Indian J Pharmacol. 2002;34:409–15.
Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, et al. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10mg+ metformin SR 500mg in diabetic dyslipidaemia in adult Indian patients. J Indian Med Assoc. 2008;106:464–7.
Oyedepo TA. Effect of Citrus maxima (Merr.) fruit juice in alloxan-induced diabetic wistar rats. Sci J Med Clin Trial. 2012;2012:3–8.
Brewer HB. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol Excerpta Medica. 2003;92:23–9.
Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann. Pharmacother. New York: SAGE Publications; 1998. p. 1044–52.
Olfert ED, Cross BM, McWilliam AA. Guide to the care and use of experimental animals. Can Counc Anim Care. 1993;49:49.